CURRICULUM VITAE

Part I General Information

Date Prepared: Aug 30th 2023

Name: Amit Awasthi

Office Address: Immuno-biology laboratory, Science Biotech cluster, 3rd Milestone

Gurgaon-Faridabad Expressway, Faridabad, 121 001, Haryana, INDIA

E-mail: aawasthi@thsti.res.in

awasthi005@gmail.com

Date of Birth: 3rd July 1977

Place of Birth: Bhind, Madhya Pradesh, INDIA

Citation index: Total citation: 13599

https://scholar.google.co.in/citations?user=AKaBq0cAAAAJ&hl=en

Education:

YearDegreeInstitution1997B.Sc. in BiologyJiwaji University, Gwalior, India1999M.Sc. in BiotechnologyJiwaji University, Gwalior, India

2006 Ph.D. in Biotechnology/Immunology National Centre for Cell Science, Pune, India

Postdoctoral Training:

2005-2009 Research Fellow Prof. Vijay K Kuchroo's Laboratory

Center for Neurologic Diseases Brigham and Women's Hospital

Harvard Medical School Boston, MA, USA

Academic Appointments:

Dec. 2022-till date Senior Professor Translational Health Science & Technology

Institute, Faridabad, India

2022-Nov. 2022 Professor Translational Health Science & Technology

Institute, Faridabad, India

2017-2021 Associate Professor Translational Health Science & Technology

Institute, Faridabad, India

2012-2017 Assistant Professor Translational Health Science & Technology

Institute, Faridabad, India

2009-2012 Junior Faculty Harvard Medical School, Boston, USA

Visiting Scientist:

May-Aug, 2016 Visiting Scientist Harvard Medical School, Boston, MA

Aug 2015 Visiting Scientist Harvard Medical School, Boston, MA
April-May, 2014 Visiting Scientist Harvard Medical School, Boston, MA

Editorial Boards:

2004 Ad Hoc Reviewer International Immunopharmacology.

2005 Editor of student News Letter Indian Immunology Society.

2009 Ad Hoc Reviewer Arthritis & Rheumatism
2009-present Ad Hoc Reviewer Plos One

2015-present Ad Hoc Reviewer Scientific Reports (Nature publishing group)

Ad Hoc Reviewer International Immunology

Ad Hoc Reviewer Immuno-biology
Ad Hoc Reviewer Oncology Reports
Ad Hoc Reviewer Immunologic Res

2016-present Review Editor Frontiers in Immunology

2017-Present Editorial Board Member Journal of Gastroenterology Forecast 2019-2022 Associate Editor Immunology, Journal of British Society for

Immunology

2019-present Review Editor Frontiers in pharmacology

Professional Societies:

2004-Present Indian Immunology Society Member (IIS) 2015-Present American Association of Immunologist (AAI) 2017-2018 Elected executive council member of Indian Immunology Society Member (IIS) 2017-present Nominated member of Molecular Immunology Forum (MIF) 2018-present Founding and life member of Immuno-Oncology Society of India 2018-Present Secretary, Indian Immunology Society (IIS) 2018-2021 Council Member of Federation of Immunological Societies of Asia-Oceania (FMISA) 2019-2022 Member of British Society for Immunology 2018-2021 Member of Steering Committee, Federation of Clinical Immunology Societies

Life member of Translational Research Society.

Institutional responsibilities at THSTI:

2012-present:

2019-present

- 1. Member Secretary Institutional Animal Ethics Committee (2013-)
- 2. Member Institutional Purchase Committee (2017-2019)
- 3. Member Institutional Extramural Link Committee
- 4. Member of Institutional Academic Committee (2017-Till date)
- 5. Chair of Institutional Sports Committee (2017-)
- 6. Chair of Institutional Purchase Committee (2019-)
- 7. THSTI Small Animal Facility In-Charge (2015-2020)
- 8. THSTI Immunology Core, In-Charge (2020-)
- 9. Chairperson of Purchase Committee(2022- Till date)
- 10. Chairperson of Institutional Animal ethics Committee(2022-Till date)
- 11. Chairperson THSTI Sports Committee(2022-Till date)

Institutional Responsibility outside Institute:

- Scientific Advisor Committee Member of National Institute of Research in Tribal Health (SAC Member of ICMR-NIRTH)
- Research Council Member of Norther East Institute of Science & Technology (Research council Member of CSIR-NEIST)

Award and Honors:

Junior Research Fellowship, Department of Biotechnology,

Government of India.

2003 Senior Research Fellowship, Council of Scientific & Industrial Research

Government of India.

2004 G.P. Talvar Young Scientist Award of Indian Immunology

Society, India.

<u> </u>	
2007	Second place (Trophy and cash prize) at 2 nd Abstract Competition at Medimmune,
	Inc. Gaithersburg, MD, USA.
2008	Tykeson Fellows Conference of Multiple Sclerosis Society, Nov 4-7, 2008 Chicago,
2040	USA. Tukanan Fallawa Canfaranan of Multiple Salarania Society, Ivan 4.7, 2010 San
2010	Tykeson Fellows Conference of Multiple Sclerosis Society, June 4-7, 2010 San Antonio, USA.
2007–2010	National Multiple Sclerosis Society Postdoctoral Fellowship, National Multiple
2007-2010	Sclerosis Society, New York, USA
2009	Travel Award, Federation of Clinical Immunology Society (Focis)
2011	Research pilot grant from Crohn's and Colitis Foundation of America, New York,
	USA
2011	Ramalingaswami Fellowship from Department of Biotechnology, India
2011	Innovative Young Biotechnologist Award from Department of Biotechnology,
	Govt. of India.
2012	Young scientist platinum jubilee award in biological sciences, National
	Academy of Sciences of India.
2013	Attended annual meeting of American Association of Immunologist, Hawaii, USA
2015	Poster presented at Federation of Clinical Immunologist Society (Focis) at San
2015	Diego, USA Poster presented at 4 th European Immunology Congress, Vienna, Austria
2016	AAI Early Career Faculty Travel Grant for attending AAI annual meeting at
2010	Seattle, Washington
2016	AAI Travel Grant for the International Congress of Immunology 2016 (ICI
	2016), Melbourne Australia
2017	G.P. Talwar Mid Career Scientist Award of Indian Immunology Society India
2017	AAI Early Career Faculty Travel Grant for attending annual meeting of American
	Association of Immunologists at Washington D.C.
2018	Early Career Award from Dutch Society of Immunology, Amsterdam for
	attending European Congress of Immunology.
2018	Travel Award from American Association of Immunologists for attend
0040	European Congress of Immunology at Amsterdam from 2 nd – 5 th September 2018
2019	Travel Award from 2 nd Human and Translational Immunology Conference
	(Co-organised by Nature Immunology), at Kos Greece from May 29 th – June 3 rd 2019.
2020	Travel Award from Gordon Research Conference 2020 to attend "Food Allergy,
2020	Gordon Research Conference (Jan 5 th – 10 th , 2020), Ventura Beach Marriott,
	Ventura CA USA
2021	GN Ramachandran National Bioscience Award for Career Development,
	Department of Biotechnology, Govt. of India.
2021	Most Impact research group of THSTI.
2022	Best publication in the year of 2022 at THSTI.
2022	CDRI Award in Life Science category for Drug Discovery.
2022	Elected member of Guha Research Conference (GRC)-2021
2022	Excellence in Research on Immune-Therapies at the 49th Annual Conference
0000	of Indian Immunological Society, PGIMER, Chandigarh.
2023	Travel Award received for attending "3rd Human & Translational Immunology
	Conference", to be held in October 23 – October 28, 2023 on Rhodes island,
2023	Greece. Travel Award received from IUIS International Congress of Immunology, Cape
LULJ	Town to be held 27 November – 2 December 2023 at the Cape Town International
	Convention Centre (CTICC).
	33.113.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.11.33.1

Part II: Research Contributions

Major Research Interests:

1. Immune regulation and interplay between effector and regulatory T cells in autoimmunity and infection

- 2. Understanding the role various subsets of Th cells in anti-tumor immunity and role of check point inhibitors in enhancing anti-tumor immune Th response
- 3. Understand the pathophysiology and vaccine development of COVID19 and Flu.

2. Narrative description of research and significant contribution:

Dr. Amit Awasthi, currently heading Immuno-Biology & Immunology Core laboratory, is a Senior Professor at THSTI, Faridabad. He is an internationally renowned immunologist with significant research contribution in the field of T cell biology in inflammatory and infectious diseases. He has published > 70 publications with several seminal papers, in the field of Immunology, in prestigious international journals such as Nature, Nature Immunology, Nature Communications, Science Advances, and Lancet Infectious Diseases with an h-index of 31 and >13000 citations. He has been conferred with many prestigious awards including 'Innovative Young Biotechnologist Award' and 'GN Ramachandran National Bioscience Award' presented by Department of Biotechnology, 'CDRI Award' for excellence in Drug Discovery research presented by CSIR-Central Drug Research Institute, 'GP Talwar Mid Career Award' by Indian Immunology Society, and 'Young scientist platinum jubilee award' by National Academy of Sciences of India. He is the Secretary-General of the 'Indian Immunology Society, a founding member immune-oncology Society of India, and an Executive Council Member of Federation of Immunological Societies of Asia-Oceania (FIMSA).

Amit is working in THSTI since 2012 in the field of T cell biology in inflammatory diseases including bowel disease (IBD). He had secured prestigious India-Alliance intermediate fellowship. Amit significantly contributed in understanding the biology of IL-9-producing helper T cells subsets (Th9) in tissue inflammation of autoimmune diseases, allergic inflammation and extracellular infections. His seminal work in discovering and identifications of transcriptional landscape of Th9 cells (Nature Immunology 2008; Nature Communications 2017; Front Immunol. 2019; Scientific Reports 2020; Nature Communications 2021) were well recognised globally. Amit has shown that ATP-triggers Th9 cell differentiation via mTOR-HIF1-a axis. Th9 cells shown to be crucial in inducing anti-tumor functions. Amit has further identified that PP2A, a phosphatase, is essential for the generation and anti-tumour functions of Th9 cells. Last year, his group has identified that Areg-EGFR activation-induced HIF-1 alpha is essential for the generation and functions of Th9 cells.

His laboratory works on crosstalk of between immune and cancer cells to determine the factors that are critical in eradication of tumour. He recently identified as to how 'Salt' activate immune system to and irradicate tumour (Science Advances 2021). His work on 'Salt and tumour' was highlighted in many renounced science magazine and news internationally. In addition, Amit has contributed significantly in functions and the transcriptional signature of pathogenic and non-pathogenic Th17 cells in autoimmune disease condition including IBD (Nature Immunology 2012, Nature 2013, Nature Immunology 2017, Cell Reps 2020, Frontiers in Immunology 2016, Scientific Reports 2017, J Leukoc Biol 2016, Cell Reps 2019).

Amit has contributed significantly in Covid19 pandemic by establishing 'cellular immunology' (Lancet Infectious Diseases, 2022) and animal models platform. In fact, Amit has shown, for the first time, that Covid19 causes cardiovascular dysfunction in hamster model (Elife 2022). His laboratory tested preclinical efficacy of Covid19 vaccine candidates including ZycovD, first DNA vaccine, and Corbevax, a subunit vaccine. His laboratory provided cellular immune response data for clinical trials of Sputnik V and Corbevax. These vaccines, subsequently, given emergency use authorisation by DCGI.

3. Research funding information:

Present Research Support:

Sr. No	Title of Project (With project file/ref.no)	Source of Funds	Total budget sanctioned	Start Date	End Date
1	"Design, Validation and Development of novel peptidomimetic therapeutics targeting SARS-Cov2 replication". File no-IPA/2020/000285	SERB- DST	11516440.00	26/10/2020	25/10/2023

2	"Development and Evaluation of diagnostic Candidate Vaccines for emerging SARS- Coronavirus-2(DEC-VAC SARS) File no-IPA/2020/000070	SERB- DST	18413480.00	18/11/2020	17/11/2023
3	INCENTIVE-"Indo-European Consortium for Next Generation Influenza Vaccine Innovation". File no-BT/IN/EU-INF/16/AP/19-20	DBT	424222198.00	29/12/2020	28/12/2025
4	ENDFLU-"Evaluation of Rationally Designed Influenza Vaccine" File no-BT/IN/EU-INF/15RV/19-20	DBT	274055952.00	31/12/2020	30/12/2025
5	"Towards an mRNA vaccine platform" File no- File no-ILSF/GRANTS2021- 22/001/28062021	IGNITE Life Science, IISC Bangalor	4054820.00	28/06/2021	27/06/2024
6	Understanding the generation, regulation and function of Th9 cells in inflammatory diseases. File no-BT/HRD/NBA-NWB/39/2020-21	NBA- DBT	1700000.00	18/08/2021	17/08/2024
7	Evaluation of the magnitude, kinetics and longevity of humoral and cellular immune responses to SARS-Cov2 variants in vaccinated and naturally infected individuals. File no-CTU/Cohort study/17/10/22/2021/ECD	ICMR	5698372.00	01/02/2022	31/01/2023
8	Multi-epitope, Nanoparticle based broadly protective Beta coronavirus candidate vaccine	THSTI PANACI A biotech	970540000.00	24/02/2022	24/02/2026
9	Identification and characterization of small molecules to block PD1/PDL1 pathway in immunotherapy. File no-BT/PR28133/NER/95/1383/2018	DBT	6335520.00	30/03/2022	29/03/2025
10	SARS-CoV-2 animal challenge model for pre- clinical and translational research. REOI-2- BT/CS0054/05/21	BIRAC	94770000.00	08/04/2022	07/04/2023 Extension requested
11	SARS-CoV2 anti-viral activity testing platform to support the preclinical development of new chemical entities, and natural products from Academia, Start-ups and Pharma companies. Ref. No: BT/CTH0004/CTH/01/20	BIRAC	47854000.00	05/09/2022	04/09/2024
12	Exploration of Immunopathogenesis of extraintestinal organ involvement in patients with Celiac disease. Ref. no- 61/08/2022-IMM/BMS	ICMR	7260000.00	18/01/2023	17/01/2026

Past Research Support:

Sr. No	Title of Project (with project file/ref.no)	Source of Funds	Total budget sanctioned	Start Date	End Date
1	"IL-27 dependent regulation of TH 17 and regulatory cells". File no BT/05/IYBA/2011	IYBA-DBT	3881000.00	03/07/2012	31/03/2017
2	"Interplay between effector and regulatory T cells in the pathogenesis of intestinal inflammation". File no IA/I/12/1/500524	DBT- Wellcome Trust	32503526.00	12/07/2012	31/08/2017
3	"Vitamin A is the "Microenvironmental cue" for triggering disease activity in patients with Inflammatory Bowel disease". File noBT/PR4763/MED/30/895/2012	DBT	82380000.00	05/03/2013	31/03/2017

4	"Human Gastrointestinal Immunology Translational Program". File no BT/PR14929/MED/15/67/2010	DBT	14458000.00	16/12/2014	18/03/2018
5	"ATX axis in satellite cells and muscle repair". File noBT/PR13045/BRB/10/1461/2015	DBT	150000.00	10/03/2017	09/03/2020
6	Sub-Network 2: Preclinical and pharmacokinetics evaluation of selected AYUSH herbal extracts/formulations for mitigating SARS-CoV-2 Virus and COVID-19 disease. File no-BT/PR40378/TRM/120/486/2020	DBT & Min. of Ayush.	49685000.00	24/08/2020	31/03/2023
7	"Understanding the transcriptional landscape of IL-10-producing anti-inflammatory T cells in IBD". File no- CRG/2018/002653	SERB-DST	5701600.00	19/12/2019	18/06/2023
8	Cellular Assay platform for determining the immunogenicity of vaccine candidates. File no-BT/CS0010/CS/02/20	BIRAC	48601200.00	22/03/2021	22/06/2023

Invited Presentations:

Bhopal.

1. 2005	Oral presentation at Department of Pathology, University of Chicago (May 23, 2005) on
	"Biology and cell signaling in parasitic infection".
2. 2008	Invited speaker at Annual meeting of Indian Immunology Society, Bhubaneshwar, India.
3. 2009	Young Researchers Travel Award Federation of Clinical Immunology Societies.
	Focis, San Francisco, USA.
4. 2012	Invited speaker and panelist, Young Investigator Meeting, Boston, USA
5. 2012	Invited talk at Children Hospital and Harvard Medical School, Boston, MA, USA
6. 2012	Special lecture at 4th Women Scientist Program at C. R. Rao AIMCIS, Hyderabad
7. 2013	Oral presentation at Harvard-AIIMS GI Immunology Conference, New Delhi
8. 2013	Plenary talk at IBD conference at G.B. Pant Hospital, New Delhi
9. 2013	Invited presentation at Indian Institute of Science, Education and Research (IISER),

- Invited as Young Investigator at 6th Young Investigator Meeting at Hyderabad. 10. 2014
- 11. May 13th, 2014 Invited speaker at Massachusetts General Hospital, Harvard Medical School "Induction and development of pathogenic Th17 cells and their regulation"
- 12. May 15th, 2014 Invited speaker at Oakland University, Michigan "Induction and development of pathogenic Th17 cells and their regulation"
- 13. March 27th, 2015 Invited speaker at Biosparks, School of Life Sciences, Jawaharlal Nehru University (JNU). New Delhi
- 14. June 24th -27th Poster presentation at Focis 2015 at San Diego California USA
- 15. Sep 6th- 9th 2015 Poster presentation at European Congress of Immunology, Vienna, Austria
- 16. Oct. 9th 11th, 2015, Invited lead talk at annual meeting of Indian Immunology Society, Patna, India
- 17. Oct 14th, 2015, Invited as an International speaker at Academy of Immunology and Microbiology (AIM), IBS, South Korea
- 18. 13th 17th May, 2016 Poster presentation at annual meeting of American Association of Immunologists at Seattle, Washington, USA
- 19. 1st Aug, 2016. Invited speaker at Emory Vaccine Center, Atlanta USA "Understanding transcriptional regulation of IL-9 in Th9 and Th17 cells in health and diseases"
- 20. 2nd Aug, 2016. Invited speaker at Nebraska Medical Center, Omaha, USA. "Understanding transcriptional regulation of IL-9 in Th9 and Th17 cells in health and diseases."
- 21. 21st 26th Aug, 2016 *Oral Presentation* at International Congress of Immunology, Melbourne, Australia.

- 22. 12th 16th May, 2017 **Poster presentation at** annual meeting of American Association of Immunologists at **Washington D.C., USA**
- 23. 26th 30th June, 2017. Invited speaker UGC KIIT/KIMS faculty development program KIIT University, Bhubaneswar.
- 24. July 20th, 2017, Invited speaker at School of Biomedical Sciences, **The Chinese University of Hong Kong, Shatin, N. T., Hong Kong.**
- 25. Sep 4th, 2017, Invited talk at Indian Institute of Sciences, Bengaluru.
- 26. October 12th 13th, 2017, Invited speaker at National Workshop on Advancement in Immunology, Vallabhbhai Patel Chest Institute, University of Delhi
- 27. Nov 16th 19th, 2017, Invited speaker at 86th Congress of Society of Biological Chemists (SBC2017), JNU New Delhi.
- 28. Dec 14th 15th, 2017, Invited Key Note Lecture at 13th National Research Scholars Meet 2017, ACTREC, Tata Memorial Centre, Mumbai.
- 29. Dec 15-16, 2017, Invited talk at Immunocon, **44**th **annual meeting of Indian Immunology Society, Nirma University, Ahmadabad.**
- 30. Jan 23rd, 2018, Invited speaker at BioSpark, Jawaharlal Lal Nehru University, New Delhi.
- 31. 26th June, 2018. Invited speaker UGC KIIT/KIMS faculty development program KIIT University, Bhubaneswar.
- 32. 10th 11th August, 2018, Invited speaker at National Seminar on Mechanisms of Immune responses at Banaras Hindu University, India.
- 33. August 18th 19th, 2018, Invited speaker at SIRCON 2018 (Society if Inflammation research), Bengaluru, India
- 32. September 2nd 5th, 2018, Oral presentation at **European Congress of Immunology, Amsterdam**.
- 34. 24th to 27th October 2018, invited speaker at 45th **National Conference of the ACBICON2018**, Kala Academy, Goa, India
- 35. 10th 13th November, 2018, Oral presentation at **The Federation of Immunological Societies of Asia-Oceania Congress** (FIMSA 2018), Bangkok, Thailand.
- 36. 28th November 2nd December, 2018, Oral presentation at **42nd Annual Conference of Indian Association of Medical Microbiologists (MICROCON2018)**
- 37. November 26th 30th, 2018, Invited speaker at **INSPIRE** programme, Department of Science & Technology, Govt. of India at AMITY University, Jaipur
- 38. December 16th 18th, 2018, Invited speaker at Bioprocessing India, Indian Institute of Technology, New Delhi.
- 39. January 12th, 2019, Invited speaker at Cancer Immunotherapy workshop, Delhi Tumour Board, Pride Plaza, Aerocity, New Delhi
- 40. January 30th, 2019, Invited Speaker at Sun Pharma, New Delhi.
- 41. February 7th 9th, 2019, Speaker at Molecular Immunology Forum at Hyderabad, India
- 42. March $1^{st} 3^{rd}$, 2019, Invited Speaker at International Symposium on Frontiers in development and molecular medicine: model to insight, IICB Kolkata.
- 43. March 8th 10th, 2019, Invited Speaker at International Conference on Molecular Basis of Diseases and Therapeutics, Central University of Rajasthan, Kishangarh, Ajmer, India
- 44. March 15th 17th, 2019, Invited Speaker at 1st Immuno-oncology Society of India Congress 2019 at Tata Memorial Centre, Mumbai, India
- 45. May 29th June 3rd 2019, **Invited Speaker at 2nd Human Translational Immunology Conference at Kos, Greece.**

- 46. June 17th, 2019, Invited Speaker at **Department of Molecular Genetics and Microbiology, Stony Brooks University, New York USA.**
- 47. Oct 12th 16th 2019, Speaker at IUIS-IIS-FIMA Immunology Course at RUHS Jaipur.
- 48. Oct $19^{th} 23^{rd}$, 2019, Invited speaker at International Congress of Immunology (IUIS), Beijing, China.
- **49.** Nov 7th 9th, 2019, Invited speaker at 5th International Conference on Translational Research: Recent Trends in pretranslational to translational research. NCCS, Pune.
- 50. Nov 14th 16th, 2019, Invited speaker at 46th Immunocon at BARC Mumbai.
- 51. Dec 19th 21st, 2019, Invited speaker at "National Conference on Nano/Bio-Technology (NanoBioTech-2019).
- 52. Jan 5th 10th, 2020, Invited speaker at "Food Allergy, Gordon Research Conference 2020, Ventura Beach Marriott, Ventura CA USA
- 53. March 3rd 5th, 2020, Invited speaker at Flow cytometry workshop NIRMA University Ahmedabad.
- 54. Oct 8th 10th 2020, Invited speaker at IIS-FIMSA online Immunology Course
- 55. 29 April, 2021, Invited speaker on World Immunology day at NII, New Delhi (Conducted Virtually).
- 55. 29 April, 2021, Invited speaker on World Immunology day at IIT Roorkee (Conducted Virtually).
- 56. 29 April, 2021, Invited speaker on World Immunology day at Central University of Punjab (Conducted Virtually).
- 57. Oct 31st- Nov 3rd, 2021, Invited speaker at 8th FIMSA Congress at Bhusan Korea.
- 58. Invited speaker for Covid19 virtual symposium held at CIDR, IISC Bangalore on 10th Nov 2021.
- 59. Invited speaker SBCI Meeting held on 16th -18th Dec 2021(Virtually conducted).
- 60. Dec 18th -19th, 2021, Invited speaker at 47th Annual meeting of Indian Immunology Society (Virtually conducted).
- 61. Invited as distinguished speaker at 2nd International RMBPD, Delhi University on 24-25 Feb 2022.
- 62. Invited speaker to 41st International Annual Conference of the Indian Association for Cancer Research (IACR-2022) on "Combating Cancer: Biology to Therapy to Drug Resistance, AMITY University NOIDA on 2-5th March 2022.
- 63. Invited as key note speaker to NIRMA University, Ahmedabad on 6th Sept 2022.
- 64. Invited talk on "Preparedness and Technological Solutions for Management of Future Pandemics: Lessons Learnt From Covid-19" at DRDE, Gwalior on 26-30th Sept 2022.
- 65. To deliver Guest Lecture and Interactive Session at GLA university, Mathura on 16th Dec 2022.
- 66. Invited Speaker for National Conference on Biotechnology held at MKU Madurai on 23-24th March 2023.
- 67. Apr 29th 2023, Invited as a distinguished Expert Speaker to GLA University, Mathura.
- 68. Apr 29th 2023, Invited speaker to National Institute of Immunology on World Immunology Day.
- 69. July 11th-13th, Visited to Serum Institute of India for attending meeting on Vaccine design.
- 69. Aug 25th 2023, Invited speaker to ACTREC Cutting edge lecture series, ACTREC, Mumbai.

Mentoring and training:

- 1. **2008:** (May to August). Mr. Brendan Collins, undergraduate student from Boston College, Boston. Currently perusuing Ph.D. in Neurobiology at Northeastern University, Boston, MA, USA.
- 2. **2009** (May to August). Kriti Subramanyam, High School student from The Winsor School, Boston, MA, USA. Currently doing undergraduate at Harvard University, Cambridge, MA, USA.
- 3. **2009** (May to August). Hyunje Grace Cho, Undergraduate student from Harvard University, Cambridge, MA, USA.
- 4. 2011 (July to August). Eashan Kaw from Virginia, USA
- 2010-2012 Youjin Lee, Graduate (Ph.D.) student from Harvard University, Cambridge, MA, USA.
- 6. **2012-2013** Neeti Nadda, Junior Research Fellow from Translational Health Science & Technology Institute, India
- 2012-2018 Ritika Rampal, Ph.D. student from All India Institute of Medical Sciences, New Delhi, India.

- 8. 2013-2018 Sakshi Malik, Ph.D. student at Translational Health Science and Technology Institute
- 9. **2012-2014** Srikanth Elesela, Post-doc fellow (Wellcome Trust) at Translational Health Science and Technology Institute
- 10. **2013-2017** Srikanth Sadhu, Junior Research Fellow, Translational Health Science and Technology Institute
- 11. **2013-2015** Ramendrapati Pandey, Research Associate, Translational Health Science and Technology Institute
- 12. 2013-2019 Suyasha Roy, Ph.D. student, Translational Health Science and Technology Institute
- 13. **2015-2016** Muzamil Yakub Want, Post-doc fellow (Wellcome Trust) at Translational Health Science and Technology Institute
- 14. 2015 Jayant Jagessar Tiwari, summer intern from Erasmus Medical Centre in the Netherlands
- 15. 2016- 2017 Zaigham Abbas, Post-doc fellow at Translational Health Science and Technology Institute
- 16. 2016- Rajdeep Dalal, Ph.D. student, Translational Health Science and Technology Institute
- 17. 2017- Srikanth Sadhu, Ph.D. student, Translational Health Science and Technology Institute
- 18. 2017- Zaigham Abbas, National -Post-doctoral Fellow, Department of Science and Technology, Govt. of India
- 19. 2018 Sonal Joshi, Short term trainee from Pune University
- 20. 2018 Rahul Nigam, Short term trainee from Dayalbagh college, Agra.
- 21. 2018- Sugandha Narayan, Ph.D. student, Translational Health Science and Technology Institute
- 22. 2018- Upasana Madan, Ph.D. student, Translational Health Science and Technology Institute
- 23. 2019- Akshay Binayke, Ph.D. student, Translational Health Science and Technology Institute
- 24. 2018 Priyanka Yadav, Short term trainee from DIPSARU, New Delhi
- 25. 2019 Umang Beri, Short term trainee from Jamia Milia Islamia Univeristy, New Delhi
- 26. 2019 Jyotsna Dandotiya, Short term trainee from Jiwaji University, Gwalior
- 27. 2019 Chinmayee Awasthy, Short term trainee from Pune University, Pune
- 28. 2019 Tarini Vohra, Short term trainee from Manav Rachana International University Faridabad
- 29. 2019 Hardik Grover, Short term trainee from Manav Rachana International University Faridabad
- 30. 2021 Adeeba Farooq, Short term trainee from Kashmir University
- 31. 2022- Bhawna Verma, Ph.D. student, Translational Health Science and Technology Institute
- 32. 2022- Jvotsna Dandotia, Ph.D. student. Translational Health Science and Technology Institute
- 33. 2022- Neeta Adhikari, Ph.D. student, Translational Health Science and Technology Institute
- 34. 2023- Ayush Tyagi, Ph.D. student, Translational Health Science and Technology Institute
- 35. 2023-Aakash Goswami, Ph.D. student, Translational Health Science and Technology Institute
- 36. 2033- Atul Kumar, Ph.D. student, Translational Health Science and Technology Institute.

Other activities:

Event organized:

- 1) April 29th, 2015, World Immunology Day was organized at Translational Health Science and Technology Institute (**Chair of the event**)
- August 26th, 2017, Discussion meeting on Liquid Biopsy supported by Wellcome Trust/DBT India Alliance was organized at Translational Health Science and Technology Institute (Co-organizer of the event)
- 3) February 1st 4th, 2018, Cellular and Molecular Immunology Course organized at THSTI.
- 4) November 1st 3rd, 2018, Immunocon 2018, 45th Annual meeting of Indian Immunology Society at THSTI (**Convener and Organizing Secretary**)
- 5) April 1st 3rd, 2019, Cellular and Molecular Immunology Course organized at THSTI.
- 6) June 24-28, 2019, All India Institute of Medical Science, Delhi and Translational Health Science and Technology Institute workshop and hands-on-training.
- 7) Oct 12th 16th 2019, Scientific Organising Secretary of IUIS-IIS-FIMSA Translational Immunology Course at RUHS Jaipur.
- March16th 18th, 2020, Cellular and Molecular Immunology Course organized at THSTI.
- 9) October 8th-10th, 2021, 3rd Annual Meeting of Immuno-oncology Society of India (**Organizing Secretary**)

- 10) December 18th 19th, 2021, 47th Annual meeting of Indian Immunology Society at THSTI (**Organizing Committee Member**)
- 11) July 14th 2022- Inflammation, a one day Symposium at THSTI.
- 12) May 5th-8th Molecular Immunology Forum at Jim Corbett, Uttarakhand(**Organizing Secretary**).

Academics and Teaching experience

- 1) Immunology curriculum was made for Indian Institute of Technology (IIT), Mandi.
- 2) Coordinator of Immunology course for Ph.D. student at Translational Health Science & Technology Institute (2013-present): This includes teaching 32 hours teaching every semester, conducting exams and coordinating the Immunology classes with external tutors.
- 3) Immunology curriculum was prepared for Regional Centre for Biotechnology, Faridabad, India
- 4) Teaching Immunology to M.Sc.-Ph.D. integrated program at Regional Centre for Biotechnology (RCB). 2 Credit course

Part III:

Bibliography

Original Articles

- 1. Awasthi A, Mathur R, Khan A, Joshi BN, Jain N, Sawant S, Boppana R, Mitra D, Saha B. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. Journal of Experimental Medicine 2003; 197: 1037-43.
- Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nature Medicine 2004; 10: 540-4
- 3. Bodas M, Jain N, Awasthi A, Martin S, Penke Loka RK, Dandekar D, Mitra, Saha B. Inhibition of IL-2 induced IL-10 production as principle of phase-specific immunotherapy. **Journal of Immunology 2006**; 177: 4636-43.
- 4. Korn T, Reddy J, Gao W, Bettelli E, **Awasthi A**, Petersen TR, Backstrom BT, Sobel RA, Wucherpfenning KW, Strom TB, Oukka M, Kuchroo VK. Myelin-specific regulatory T cells accumulate in the central nervous system, but fail to suppress pathogenic effector T cells at the peak of autoimmune inflammation. **Nature Medicine 2007**; **13**: **423-31**.
- 5. Korn T, Bettelli E, Gao W, **Awasthi A**, Jäger A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternate pathway to induce proinflammatory Th17 cells. **Nature 2007**; **448**: **484-7**.
- 6. **Awasthi A**, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL. A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells. **Nature Immunology 2007**; **12**:1380-9.
- 7. **Awasthi A*,** Dardalhon V*, Kwon H, Galileos G, Gao W, Strom TB, Oukka M, Kuchroo VK. IL-4 inhibits TGF-b-induced-Foxp3⁺T cells and generates a Foxp3⁻ IL-10/IL-9 T cell population. **Nature Immunology 2008**; 9:1347-55 [*Equal first authorship].
- 8. Korn T, Mitsdoerffer M, Croxford AL, **Awasthi A**, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK, Oukka M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ T-regs. **Proceeding of National Academy of Science USA 2008**; **105**:18460-5.
- 9. Awasthi A, Riol-Blanco L, Jäger A, Korn T, Pot C, Galileos G, Bettelli E, Kuchroo VK, Oukka M. Cutting Edge: IL-23 receptor reporter mice reveal distinct populations of IL-17 producing cells. Cutting Edge: Journal of Immunology 2009; 182: 5904-08.
- Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, Bettelli E, Oukka M, van Snick J, Renauld JC, Kuchroo VK, Khoury SJ. Reciprocal role of IL-9 in regulation of immunity: Enhancement of T-regs functions and Th17 differentiation. Proceeding of National Academy of Science USA 2009; 106:12885-90.
- 11. Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC, Kuchroo VK. Cutting Edge: IL-27 Induces the Transcription Factor c-Maf, Cytokine IL-21, and the Costimulatory Receptor ICOS That Coordinately Act Together to Promote Differentiation of IL-10-Producing Tr1 Cells. Cutting Edge: Journal of Immunology 2009; 183: 797-801.
- 12. **Awasthi A**, Kuchroo VK. IL-17A directly inhibits T_H1 cells and thereby regulates development of intestinal inflammation. **Nature Immunology 2009; 10:568-70.**

- 13. Awasthi A, Kuchroo VK. Yin and Yang of follicular T cell development. Science 2009; 325:953-5.
- 14. Riol-Blanco L, Lazarevic V, **Awasthi A**, Mitsdoerffer M, Wilson BS, Waisman A, Kuchroo VK, Glimcher LH & Oukka M. IL-23 receptor regulates unconventional IL-17-producing T cells that control early stages of infection. **Journal of Immunology 2010**; **184:1710-20**.
- 15. Putheti P, **Awasthi A**, Gao W & Strom TB. IL-4 and TGF-□ induce human memory T cells to become IL-9+CD4+ T cells. **PlosOne 2010**; **5**: **e8706**.
- 16. Awasthi A, Kuchroo VK. Value added, Neural progenitor cells suppress inflammation and autoimmunity. Immunity 2011; 35:156-7.
- 17. Lee Y*, Awasthi A*, Yosef N, Quintana F, Xiao S, Kunder S, Regev A, Sobel R, Kuchroo VK. Induction and molecular signature of pathogenic T_H17 cells. Nature Immunology 2012; 13:991-9 [Shared first and Co-senior author].
- 18. Yosef N, Shalek AK, Gaublomme J, Jin H, Lee Y, **Awasthi A**, Wu C, Karwacz K, Park H, Kuchroo VK, Regev A. Reconstruction of the dynamic regulatory network that controls Th17 cell differentiation by systematic perturbation in primary cells. **Nature 2013, 25;496:461-8.**
- 19. Tyagi RK, Garg NK, Jadon R, Sahu T, Karare OP, **Awasthi A,** Marepally SK, Elastic liposome mediated transdermal immunization enhanced the immunogenicity of P. falciparum surface antigen, MSP-1. **Vaccine 2015**, 33: 4630-8
- 20. Tyagi R, Garg N, Dalai S, **Awasthi A.** Transdermal immunization of P. falciparum surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity. **Human Vaccine & Therapeutics 2016 Jan 25:0.**
- 21. Sankhyan A, Sharma S, Dutta D, Chosdol K, Wakita T, Watashi K, **Awasthi A**, Acharya SK, Khanna N, Tiwari A, Sinha S. Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals. **Sci Rep 2016**; **6:21240**.
- 22. Rampal R, Awasthi A, Ahuja V. Retinoic acid primed human dendritic cells promote gut-tropism, inhibit Th9 cells and induce Th1/Th17 cell differentiation. J Leukoc Biol 2016; jlb.3VMA1015-476R
- 23. Chihara N, Madi A, Karwacz K, **Awasthi A**, Kuchroo VK. Differentiation and characterization of Tr1 cells. **Current Protocols in Immunol 2016**; **113:3.27.1-3.27.10**
- 24. Khalili H, Malik S, Ananthakrishnan A, Garber J, Higuchi L, Joshi A, Peloquin J, Richter J, Stewart K, Curhan G, **Awasthi A***, Yajnik V, Chan A. Dietary Sodium and Potassium Intake, Immune Tolerance and Risk of Crohn's Disease and Ulcerative Colitis. **Frontiers in Immunology 2016**;7:554. doi: 10.3389/fimmu.2016.00554. (*Shared senior author)
- 25. Gu G, Huang Y, Wu C, Guo Z, **Awasthi A***, He X, Differential expression of long noncoding RNAs during cardiac allograft rejection. **Transplantation 2017,101:83-91.doi:** 10.1097/TP.000000000001463 (*Shared senior author).
- 26. Malik S, Dardhalon V, **Awasthi A**. Role of Th9 cells in EAE and IBD: Lessons learnt from adoptive transfer experiments. **Methods in Mol Biol 2017,** pp.201-216, DOI: 10.1007/978-1-4939-6877-0 16·
- 27. Karwacz K, Miraldi ER, Pokrovskii M, Madi A, Yosef N, Wortman I, Chen X, Watters A, Carriero N, Awashti A, Regev A, Bonneau R, Littman D, Kuchroo VK. Critical role of IRF1 and BATF in preparing the chromatin landscape during Tr1 differentiation. Nature Immunology 2017, 18(4):412-421. doi: 10.1038/ni.3683.
- 28. Malik S, Sadhu S, Elesela S, Pandey R, Rathod D, Amanpreet Chawla, Sharma D, Ghosh B, Ahuja V, **Awasthi A**. Transcription factor Foxo1 essential for differentiation of IL-9+ T helper cells. **Nature Communications 2017**, **8**(1):815. **doi:** 10.1038/s41467-017-00674-6.
- 29. Goyal S, Rampal R, Kedia S, Mahajan S, Bopanna S, Yadav D, Jain S, Singh A, Wari NM, Makharia G, Awasthi A*, Ahuja V. Urinary potassium is a potential biomarker of disease activity in Ulcerative colitis and displays in vitro immunotolerant role. Scientific Reports 2017. (*Shared senior author), Dec 22;7(1):18068. doi: 10.1038/s41598-017-18046-x.
- 30. Malik S, **Awasthi A.** Transcriptional Control of Th9 Cells: Role of Foxo1 in Interleukin-9 Induction. **Front Immunol 2018** May 9;9: 995. doi: 10.3389/fimmu.2018.00995.
- 31. Roy S, **Awasthi A**. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. **Front in Immunol 2019**, 9:3036. doi: 10.3389/fimmu.2018.03036.
- 32. Roy S, **Awasthi A.** ATP Triggers Human Th9 Cell Differentiation via Nitric Oxide-Mediated mTOR-HIF1α Pathway. **Front Immunol.** 2019, 10:1120. doi: 10.3389/fimmu.2019.01120.

- 33. Roy S and Awasthi A. Emerging roles of non-coding RNAs in T cell differentiation and functions in autoimmune diseases. International Review of Immunology 2019, 38:232-245. doi: 10.1080/08830185.2019.
- 34. Chandwaskar R, **Awasthi A**, Emerging roles of Th9 cells as an anti-tumor helper T cells. **International Review of Immunology 2019**, 38(5):204-211. doi: 10.1080/08830185.2019.
- 35. Sohail A, Abbas ZA, Ahuja V, **Awasthi A***, Srikanth CV. DeSUMOylase SENP7 mediated epithelial signalling triggers intestinal inflammation via expansion of Gamma-delta T cell. **Cell Reps 2019**, Dec 10;29(11):3522-3538.e7. doi: 10.1016/j.celrep.2019.11.028. (*Co-corresponding author)
- 36. Pal S, Medatwal N, Kumar S, Kar A, Komalla V, Yavvari PS, Mishra D, Rizvi ZA, Nandan S, Malakar D, Pillai M, **Awasthi A**, Das P, Sharma RD, Srivastava A, Sengupta S, Dasgupta U, Bajaj A. A localized chimeric hydrogel therapy combats tumor progression through alteration of sphingolipid metabolism. **ACS Central Science 2019**, 5(10):1648-1662. doi:10.1021/acscentsci.9b00551.
- 37. **Awasthi A**, Kumar H. T cell subtypes and its therapeutic potential in autoimmune diseases and cancer. **Int Rev Immunol 2019**, 385:181-182. doi: 10.1080/08830185.2019.
- 38. Goswami R, **Awasthi A.** T Cell Differentiation and Function in Tissue Inflammation. **Front Immunol.** 2020 Feb 21;11:289. doi: 10.3389/fimmu.2020.00289.
- 39. Roy S, Asthana A, Goyal R, Yadav AK, **Awasthi A**. Proteome analysis revealed the essential functions of PP2A in the induction of Th9 cells. **Scientific Reports 2020**, 10:10992. doi: 10.1038/s41598-020-67845-2.
- 40. Samal S, Shrivastava T, Sonkusre P, Rizvi ZA, Kumar R, Ahmed S, Bansal M, Chauhan K, Pokhrel S, Tambare P, Awasthi A. Influenza A H1N1 M2e soluble immunogen derived from mammalian expression system form higher order oligomers and show enhanced immunogenicity in vivo. J Biol Chem 2020, jbc.RA120.013233. doi: 10.1074/jbc.RA120.013233.
- 41. Zhang H, Madi A, Yosef N, Chihara N, Awasthi A, Pot C, Lambden C, Srivastava A, Burkett PR, Nyman J, Christian E, Etminan Y, Lee A, Stroh H, Xia J, Karwacz K, Thakore PI, Acharya N, Schnell A, Wang W, Apetoh L, Rozenblatt-Rosen O, Anderson AC, Regev A, Kuchroo VK. IL-27 driven transcriptional network identifies regulators of IL-10 expression across T helper cell subset. Cell Reps 2020, 33:108433. doi: 10.1016/j.celrep.2020.108433.
- 42. Rampal R, Saurabh Kedia, **Awasthi A**, Ahuja A. Retinoic acid is elevated in the mucosa of patients with active ulcerative colitis and displays a pro-inflammatory role by augmenting IL-17 and IFNγ production. **Inflammatory Bowel Diseases 2021**, 27:74-83. doi: 10.1093/ibd/izaa121
- 43. Mittal L, Srivastava M, Kumari A, Tonk RK, **Awasthi A***, Asthana S. The interplay among structural stability, plasticity and energetics is determined by conformational attuning of flexible loops of PD-1. **Journal of Chemical Information and Modelling 2021**, 61:358-384. doi: 10.1021/acs.jcim.0c01080. *Co-corresponding author
- 44. Roy S, Rizvi ZA, Clarke A, Macdonald F, Pandey A, Zaiss D, Dr. Simon KA, **Awasthi A**. EGFR-HIF1α signaling positively regulates the differentiation of IL-9 producing T helper cells. **Nature Communication 2021**, 12(1):3182. doi: 10.1038/s41467-021-23042-x
- 45. Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R, Maiti TK, Tiwari A, Pandey AK, **Awasthi A**. EGFR-HIF1a axis is essential for the intracellular survival of *Salmonella*. **Front Immunol. 2021**, 12:648710. doi: 10.3389/fimmu.2021.648710.
- 46. Vishwakarma P, Yadav N, Rizvi ZA, Khan NA, Chiranjivi A, Shrivastava T, Bansal M, Dwivedi P, Kumar R, **Awasthi A**, Ahmed S, Samal S. Characterization of SARS-CoV2 Spike Protein Synthetic Peptides as potential targets for vaccine and therapeutics. **Front Immunol. 2021**, 12:613045. doi: 10.3389/fimmu.2021.613045.
- 47. Chauhan S, Rathore DK, Lacroix-Desmazes S, Gupta N, **Awasthi A**, Vrati S, Kalia M. Japanese encephalitis virus infected human monocyte-derived dendritic cells activate a transcriptional network leading to an antiviral inflammatory response. **Front Immunol. 2021**, 12:638694. doi: 10.3389/fimmu.2021.638694.
- 48. Ganneru B, Jogdand H, Dharam VK, Mulugu N, Prasad B S, Srinivas VK, Ella K, Ravikrishnan R, Awasthi A, Jose J, Rao P, Kumar D, Abraham P, Yadav P, Sapkal G, Shete A, Deshpande GR, Mohandas S, Basu A, Gupta N, Bhargava B, Mohan K, Ella R. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine BBV152. iScience 2021, 24 (4):102298. doi: 10.1016/j.isci.2021.102298
- 49. Lin X, Gaudino S, Roy S, Castillo P, Elsegeiny W, Wakabayashi N, Oury TD, Pociask D, Chen K, **Awasthi A**, Kolls JK and Kumar P. Nrf2 differentially regulates IL-22 and IL-17A response in CD4+

- T cells_through Ahr and SOD3 axis. **Journal of Immunology 2021**, 206 (7); 1540-1548; doi: 10.4049/jimmunol.1900656.
- 50. Yadav N, Vishwakarma P, Khatri R, Siddqui G, **Awasthi A**, Ahmed S, Samal S. Comparative Immunogenicity analysis of Intra dermal and Intra muscular administration of SARS-CoV2 RBD epitope peptide-based Immunogen. **Microbes and Infection 2021**, 23(4-5):104843. doi: 10.1016/j.micinf.2021.104843.
- 51. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, **Awasthi A**, Surjit M. Comparative immunomodulatory evaluation of the receptor binding domain of SARS CoV-2 spike protein; a potential vaccine candidate, imparts potent humoral and Th1 type of immune response in a mouse model. **Front Immunol. 2021**, 12:641447. doi: 10.3389/fimmu.2021.641447.
- 52. Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, Tripathy MR, Rathore DK, **Awasthi A**. High salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. **Science Advances 2021,** 7(37):eabg5016. doi: 10.1126/sciadv.abg5016.
- 53. Mittal L, Tonk RK, **Awasthi A**, Asthana S. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. **Arch Biochem Biophys. 2021**, 713:109059. doi: 10.1016/j.abb.2021.109059
- 54. Rizvi ZA, Tripathy MR, Sharma N, Goswami S, Srikanth N, Sastry JLN, Mani S, Surjit M, **Awasthi A***, Dikshit M. Effect of prophylactic use of intra-nasal oil formulation in the hamster model of Covid19. **Frontiers in Pharmacology 2021**, Oct 14;12:746729. doi: 10.3389/fphar.2021.746729. *Co-corresponding author
- 55. Thiruvengadam R, Awasthi A, Medigeshi GR, Bhattacharya S, Mani S, Sivasubbu S, Shrivastava S, Samal S, Murugesan DR, Desiraju BK, Kshetrapal P, Pandey R, Scaria V, Malik PK, Taneja J, Binayke A, Vohra T, Zaheer A, Rathore D, Khan NA, Shaman H, Ahmed S, Kumar R, Deshpande S, Subramani C, Wadhwa N, Gupta N, Pandey AK, Bhattacharya J, Agrawal A, Vrati S, Bhatnagar S, Garg PK. Cellular Immune Responses are Preserved and may Contribute to Vaccine Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infectious Disease 2021, Nov 25:S1473-3099(21)00680-0. doi: 10.1016/S1473-3099(21)00680-0.
- 56. Thiruvengadam R, Binayke A, **Awasthi A.** SARS-CoV-2 delta variant a persistent threat to the effectiveness of vaccines. **Lancet Infectious Disease 2022, 22(3)**:301-302. doi: 10.1016/S1473-3099(21)00697-6.
- 57. Suri C, **Awasthi A***, Asthana S. RoR t agonist, inverse agonists and allosteric inhibitors- a crystallographic landscape. **Drug Discovery Today 2022**, Nov 24:S1359-6446(21)00503-1. doi: 10.1016/j.drudis.2021.11.022. *Co-corresponding author
- 58. Rizvi ZA, Dalal R, Sadhu S, Binayke A, Dandotiya J, Kumar Y, Shrivastava T, Gupta SK, Aggarwal S, Tripathy M, Rathore DK, Yadav AK, Medigeshi GR, Pandey A, Samal S, Asthana A, **Awasthi A**. Golden syrian hamster as a model to study cardiovascular complications associated with SARS-CoV2 infection. **eLife 2022**, Jan 11;11:e73522. doi: 10.7554/eLife.73522.
- 59. Thiruvengadam R, **Awasthi A**, Bhatnagar S, Garg PK. Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India Authors' reply. **Lancet Infectious Disease 2022**, 22(4):447. doi: 10.1016/S1473-3099(22)00120-7.
- 60. Hingankar N, Deshpande S, Das P, Rizvi ZA, Burns A, Barman S, Zhao F, Ansari MY, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Bhattacharyya S, Mani S, Singh S, Dandotiya J, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshi G, Ward AB, Bhatnagar S, Awasthi A, Sok D, Bhattacharya J. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant. 2022, Plos Pathogens. doi.org/10.1371/journal.ppat.1010465.
- 61. Mittal L, Tonk R, **Awasthi A**, Asthana S. Traversing through the dynamic protein-protein interaction landscape and conformational plasticity of PD-1 for small molecule discovery. **Medicinal Chemistry,2022.** doi: 10.1021/acs.jmedchem.2c00176
- 62. Khatri R, Parray HA, Agrahari AK, Rizvi ZA, Kaul R, Raj S, Asthana S, Mani S, Sweety Samal, Awasthi A, Ahmed S. Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. International Journal of Biological Macromolecules.2022. 22:S0141-8130(22)00861-3. DOI: 10.1016/j.ijbiomac.2022.04.148.

- 63. Kumar CS, Singh B, Rizvi ZA, Parray HA, Verma JK, Ghosh S, Mukhopadhyay A, **Awasthi A**, Shrivastava T, Banerjee M. Virus-like particles of SARS-CoV-2 as virus surrogates: morphology, immunogenicity, and internalization in neuronal cells. **2022**, **ACS Infectious Diseases**, doi.org/10.1021/acsinfecdis.2c00217.
- 64. Rizvi ZA, Babele P, Sadhu S, Madan U, Tripathy MR, Goswami S, Shailendra Mani, Kumar S, Awasthi A, Dikshit M. Prophylactic treatment of *Glycyrrhiza glabra* mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. Frontiers in Immunology, 2022. doi.org/10.3389/fimmu.2022.945583.
- 65. Binayke A, Zaheer A, Dandotiya Y, Kumar Y, Mani S, Madan U, Tripathy MR, Gupta SK, Shrivastava T, Rathore DK, Pandey AK, Awasthi A. Proinflammatory innate cytokines and metabolomic signatures predict T cell response in active COVID-19. **Vaccine 2022.** doi.org/ 10.3390/vaccines10101762.
- 66. Thuluva S, Paradkar V, Turaga K, Gunneri SR, Yerroju V, Mogulla R, Suneetha PV, Kyasani M, Manoharan SK, Adabala S, Javvadi AS, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, **Awasthi A**, Singh C, Rao AV, Basu I, Khobragade AK, Pandey AK. Immunogenic superiority and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial. **medRxiv**, **doi:** https://doi.org/10.1101/2022.03.20.22271891. under advanced revision **E-Biomedicine**.
- 67. Rizvi ZA, Sadhu S, Dandotiya J, Sharma P, Singh V, Das V, Kumar R, Samal S, Kalia M, **Awasthi A**. SARS-CoV-2 and its variants, but not Omicron, induce thymic atrophy and impaired T cell development. **2022**, **submitted**. https://doi.org/10.1101/2022.04.07.487556.
- 68. Roy SS, Sharma S, Rizvi ZA, Sinha D, Gupta D, Rophina M, Sehgal P, Maiti S, Scaria V, Sivasubbu S, **Awasthi A**, Harshan KH, Jain S, Chowdhury S. Anti-COVID-19 Activity of FDA Approved Drug through RNA G-quadruplex Binding. **Submitted biorxiv.** https://doi.org/10.1101/2022.05.31.493843.
- 69. Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Srikanth Adabala, Aditya Sri Javvadi, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Akshay Binayke, Aymaan Zaheer, **Awasthi A**, Manish Narang, Pradeep Nanjappa, Niranjana Mahantshetti, Bishan Swarup Garg, Anil Kumar Pandey. Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. **Vaccine 2022**, doi.org/10.1016/j.vaccine.2022.10.045.
- 70. Ramachandran T, Rizvi ZA, Sreevatsan R, Deepika Rathna Murugesan, Mudita Gosain, Dandotiya J, Ayushi A, Sweety S, Pandey AK, Nitya Wadhwa, Shinjini Bhatnagar, Amit Awasthi, Pramod Kumar Garg. Clinical and experimental evidence suggest omicron SARS-CoV-2 is inherently less pathogenic than delta independent of previous immunity. Submitted, Research Square 2022. DOI: https://doi.org/10.21203/rs.3.rs-2258374/v1.
- 71. Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Pothakamuri SV, Turaga K, Kyasani M, Manoharan S, Adabala S, Javvadi AS, Medigeshi GR, Singh J, Shaman H, Binayke A, Aymaan Z, Awasthi A, Narang M, Pradeep N, Mahantshetti N, Garg BS, Ravi M. Safety, tolerability and immunogenicity of Biological Es CORBEVAX vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study. Vaccine 2022, doi: https://doi.org/10.1101/2022.04.20.22274076.
- 72. Parray HA, Narayanan N, Garg S, Rizvi ZA, Shrivastava T, Kushwaha S, Singh J, Murugavelu P, Anbalagan A, Mehdi F, Raj N, Singh S, Dandotiya J, Lukose A, Jamwal D, Kumar S, Chiranjivi A, Dhyani S, Mishra N, Jakhar K, Sonar S, Panchal AK, Tripathy MR, Ahamed S, Samal S, Mani S, Bhattacharyya S, Das S, Sinha S, Luthra L, Batra G, Sehgal D, Medigeshi G, Sharma C, Awasthi A*, Garg PK, Nair DT, Kumar R. A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concerns.(*Co-corresponding author). PLOS pathogen 2022. doi:10.21203/rs.3.rs-1431974/v1.
- 73. Roy, S.S., Sharma, S., Rizvi, Z.A., Sinha, D., Gupta, D., Rophina, M., Sehgal, P., Sadhu, S., Tripathy, M.R., Samal, S. and Maiti, S., 2023. G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters. *Frontiers in molecular biosciences*, 2023. 10, p.1133123.
- 74. Rizvi, Z.A., Babele, P., Madan, U., Sadhu, S., Tripathy, M.R., Goswami, S., Mani, S., Dikshit, M. and Awasthi, A., 2023. Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora

- cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. *Frontiers in Immunology 2023.* doi: 10.3389/fimmu.2023.1138215.
- 75. Khatri, Ritika, Gazala Siddqui, Srikanth Sadhu, Vikas Maithil, Preeti Vishwakarma, Bharat Lohiya, Abhishek Goswami, Shubbir Ahmed, Amit Awasthi, and Sweety Samal. "Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. *Medical Microbiology and Immunology* (2023): 1-20. DOI: 10.1007/s00430-022-00760-7.
- 76. Sadhu S, Dalal R, Dandotia J, Binayke A, Vinayak KV, Shakti K, Singh V,Goswami S, Tripathy MR, Rizvi ZA, Awasthi A. IL-9 exacerbates SARS-CoV2 infection and associated airway inflammation. Manuscript ID: NCOMMS-22-28241C, Nature Communication 2023.
- 77. Ansari S, Gupta N, Verma R, Singh O, Gupta J, Kumar a, Yadav M, Binayke A, Tiwari M, Periwal N, Sood V, Mani S, **Awasthi A**, Shalimar, Nayak B, Ranjith CT, Surjit M.K, Antiviral activity of the human endogenous retrovirus-R envelope protein against SARS-CoV-2. **Accepted in EMBO reports 2023**, Ref ID- EMBOR-2022-55900V3.
- 78. Rizvi ZA*, Sharma K, Srikanth S, Dandotiya J, Khatri R, Singh V, Adhikari N, Das V, Mani S, Samal S, Awasthi A*. Omicron sub-lineage BA.5 infection causes attenuated pathology and results in robust protection in Omicron-recovered hACE2 transgenic mice. Accepted and ahead for publication Communications Biology,2023. (ISSN 2399-3642).

Reviews

- 1. Awasthi A, Mathur RK, Saha B. Immune response to *Leishmania* infection. Indian Journal of Medical Research 2004; 119, 238-58.
- 2. Mathur RK, **Awasthi A**, Saha B. The conundrum of CD40 function: Host-protection and disease-promotion? **Trends in Parasitology 2006; 22: 117-22.**
- 3. **Awasthi A**, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. **Journal of Clinical Immunology 2008; 28:660-70.**
- 4. **Awasthi A**, Kuchroo VK. Th17 cells: from precursors to players in inflammation and infection. **International Immunology 2009**; 21:489-98.
- 5. Pot C, Apetoh L, **Awasthi A**, Kuchroo VK. Interleukin-27 as a novel cytokine to promote interleukin-10-producing regulatory type 1 (Tr1) cells development: molecular mechanisms and clinical implications. **Journal of Interferon Cytokine Research 2010; 30: 381-8.**
- 6. Awasthi A, Kuchroo VK. IL-17 and Th17 cells in immunity and autoimmunity. **E publication Focis 2011**: May issue.
- 7. Pot C, Apetoh L, **Awasthi A**, Kuchroo VK. Induction of regulatory Tr1 cells and inhibition of T_H17 cells by IL-27. **Seminar In Immunology 2011; 23:438-45.**
- 8. Kuchroo VK, Awasthi A. Emerging new roles of Th17 cells. European Journal of Immunology 2012; 42(9):2211-4.
- 9. Malik S, Muzamil Want, **Awasthi A**, Emerging role of gamma-delta T cells in tissue inflammation in EAE. **Frontiers in Immunology 2016**; **7:14.**
- 10. Vishwakarma P, Khatri R, Siddiqui G, Yadav N, Rizvi ZA, **Awasthi A**, Samal S. Preclinical animal models for COVID-19 research-making a wise choice. **ARC Journal of Immunology and Vaccines 2021**; 5: 24-37
- Sharma A, Sanduja P, Anand A, Mahajan P, Guzman CA, Yadav P, Awasthi A, Hanski E, Dua M, Johri AK. Advanced Strategies for Development of Vaccines against Human Bacterial Pathogens. World Journal of Microbiology and Biotechnology 2021, 37:67. doi: 10.1007/s11274-021-03021-6.
- 12. Gupta B, Sadaria D, Warrier VU, Makandar AI, Kant R, Sethi G, Pal JK, Awasthi A, Yuba E, Garg M, Gupta RK. Plant lectins to prepare the targeted nanovaccines for cancer immunotherapy. Seminar In Cancer Biology 2022 May;80:87-106. doi: 10.1016/j.semcancer.2020.02.005.
- 13. Saxena, Reshu, Priyanka Sharma, Sandeep Kumar, Niteshkumar Agrawal, Sumit Kumar Sharma, and **Amit Awasthi**. "Modulation of mitochondria by viral proteins." *Life Sciences* (2022): 121271. doi: 10.1016/i.lfs.2022.121271.

Book Chapters

1. Saha B, **Awasthi A**, Mathur R. Reciprocal CD40 signaling through p38MAP kinase and ERK1/2 in *Leishmania* infection. **Deep Roots Open Skies: New Biology in India 2004. p. 167-72.**

- 2. **Awasthi A**, Leu SM, Kuchroo VK. Cytokines and immune system. **HLA system in Medicine and Biology 2010** Jaypee Brothers Medical Publishers Ltd.; 1st ed. (Book Chapter) p. 19-41.
- 3. **Awasthi A** and Kuchroo VK. From T_H1/T_H2 paradigm to T_H17 cells: Le roi est mort vive le roi, **T_H17 Cells in Health and Disease 2010.** Springer (Book Chapter) p. 3-25.
- Roy S and Awasthi A. Vitamin A and Immune system. Nutrition and Immunity 2019. Springer (Book Chapter). p. 53-73.
- 5. Narayan S, Mittal L, **Awasthi A**, Asthana S. Recent Advances in Drug Development Targeting Cancer Metabolism. Cancer Cell Metabolism: **A Potential Target for Cancer Therapy 2020**. Springer (book chapter). pp 103-126. ISBN 978-981-15-1990-1
- 6. Rajdeep Dalal, Srikanth Sadhu, **Amit Awasthi**. Role of Th17 cells in tissue inflammation and organ specific autoimmunity. Translational Autoimmunity 2022. P. 93-121.

Patent filed and granted:

- 1. Patent granted: Indian Patent No. 331376 Grant on: February 05, 2020. Title: "METHOD OF PREPARING WATER SOLUBLE CHITOSAN OLIGOSACCHARIDE NANOPARTICLES BY ACID HYDROLYSIS AND USES THEREOF" Ref. no-2706/DEL/2015.
- 2. A pharmaceutical composition for the treatment of il9 mediated autoimmune inflammatory diseases and uses thereof. Application PCT/IN2018/050575. Filed date-6.9.2018. Patent ref. no-WO2019239423A1.Published date-12.12.2019.
- 3. Autophagy inducing peptides, Application PCT/IN2021/050799, Filed date-12.8.2021, Patent ref. no- WO2022038638A1, Published date-24.2.2022.
- 4. Ror antagonists, their use and method of treatment comprising the said modulators. Application PCT/IN2019/050718. Ref. patent ref. no-WO2020065682A1, Published date-2.4.2022.
- 5. Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19). Application PCT/IB2022/057923. Filed Date-24.08.2022 Patent ref. no- WO2023026207A1, Published date-2.3.2023.
- 6. Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses thereof. Application PCT/IB2022/059713, Filed date-11.10.2022, Patent ref. no-WO2023062515A1, Published date-20.4.2023.
- 7. Patent filed: Indian Patent Application No. 202211005368. NOVEL CHOLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES AND USES THEREOF. PCT filed-21.3.2023.
- 8. Awasthi A., Dalal R. A combination of succinate consuming microbiotas. Provisionally filed for the Indian patent (Application No. 202311037041).

Amit Awasthi, Ph.D Senior Professor